title: Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists.
abstract: In this work, we have highlighted data reported in the literature trying to draw a complete picture of the structures and biological activity of agonists and orthosteric antagonists of P2X receptors. Actually, only few P2X receptor agonists have been found and most of them are derived from modification of the natural ligand ATP and they are P2X receptor subtype unselective. In particular, BzATP (9) is one of the most potent P2X receptor agonists with EC50 value in the nanomolar range at some subtypes. Differently from agonists, P2X receptor antagonists belong to different chemical classes such as high molecular weight aryl polysulfonate molecules like suramin and its simplified derivatives and anthraquinone compounds. All these molecules proved to be non selective at P2X receptors, and they are endowed with micromolar activity and not favourable pharmacokinetic properties due to the presence of several charged groups. Also modification of the natural ligand ATP led to the discovery of P2X receptor antagonists like TNP-ATP (29), which, although not selective, showed high potency at P2X1, P2X3 (IC50 of 0.006 µM and 0.001 µM, respectively), and heteromeric P2X2/3 receptors. Also the dinucleotide inosine polyphosphate Ip5I (33) was found to be a potent and selective antagonist at P2X1 vs P2X3 receptors with IC50 = 0.003 µM. A significant improvement has been gained from the interest of pharmaceutical companies that in the last years discovered, through the use of high-throughput screening, potent and selective antagonists endowed with novel structures, some of which are currently in clinical trials for several therapeutic applications.
authors.forename: Catia
authors.initials: C
authors.lastname: Lambertucci
authors.forename: Diego
authors.initials: D
authors.lastname: Dal Ben
authors.forename: Michela
authors.initials: M
authors.lastname: Buccioni
authors.forename: Gabriella
authors.initials: G
authors.lastname: Marucci
authors.forename: Ajiroghene
authors.initials: A
authors.lastname: Thomas
authors.affiliation: School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino, 1, I-62032, Camerino, Italy. rosaria.volpini@unicam.it.
authors.forename: Rosaria
authors.initials: R
authors.lastname: Volpini
mesh_terms: D000818:Animals; D006801:Humans; D058919:Purinergic P2 Receptor Antagonists / Q000737:chemistry* / Q000494:pharmacology*; D058911:Purinergic P2X Receptor Agonists / Q000737:chemistry* / Q000494:pharmacology*; D058469:Receptors, Purinergic P2X / Q000737:chemistry / Q000378:metabolism
chemical_list: D058919:Purinergic P2 Receptor Antagonists; D058911:Purinergic P2X Receptor Agonists; D058469:Receptors, Purinergic P2X